Drugs / TP-1287
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03604783 | Dec 2018 → Jan 2024 | Ewing sarcoma, dedifferentiated liposarcoma, synovial sarcoma | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-1287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03604783 ↗ |
| Known as | Alvocidib phosphate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594423 ↗ |
| Known as | Alvocidib prodrug tp-1287 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594423 ↗ |
| Action | Inhibit | “the CDK9 inhibitor” NCT03604783 ↗ |
| Modality | Small molecule | — CHEMBL4594423 ↗ |
| Route | Oral | “TP-1287 by oral administration” NCT03604783 ↗ |
| Target | CDK9 | “the CDK9 inhibitor” NCT03604783 ↗ |